Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-039-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.68 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
3 Wall Street analysts have issued twelve-month target prices for CELYAD SA/ADR's stock. Their predictions range from $25.00 to $48.00. On average, they expect CELYAD SA/ADR's share price to reach $36.50 in the next year. This suggests a possible upside of 196.7% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.
What are Wall Street analysts saying about CELYAD SA/ADR stock?
Here are some recent quotes from research analysts about CELYAD SA/ADR stock:
- 1. William Blair analysts commented, "We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially registration enabling) study regimen in 2020. Celyad in June presented updated data from dose level 3 (3e9 cells given in three biweekly infusions) and initial data from cohort 10 (1e9 cells at a dense schedule of three CY AD-01 weekly infusions) of the THINK study at the European Hematology Association (EHA) 2019 meeting (EHA With CY AD-01 Dense Schedule and Preconditioning Regimens)." (8/23/2019)
- 2. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (7/17/2019)
- 3. HC Wainwright analysts commented, "We base our $46 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML and third line metastatic CRC. We use the net present value of our revenue forecast through 2026, apply a 25% POS for AML and 20% POS for CRC, a 4x price/sales multiple. We include our year-end 2018 estimated fully diluted net cash of $4.39/share (assuming €1.00 = $1.15) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x." (11/21/2018)
Has CELYAD SA/ADR been receiving favorable news coverage?
News headlines about CYAD stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CELYAD SA/ADR earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for CELYAD SA/ADR.
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Dermira (DERM), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Karuna Therapeutics (KRTX), Syros Pharmaceuticals (SYRS), Milestone Pharmaceuticals (MIST), Aptorum Group (APM), Sinovac Biotech (SVA), Advanz Pharma (CXRXF), Urogen Pharma (URGN), Crinetics Pharmaceuticals (CRNX), Organogenesis (ORGO), CytomX Therapeutics (CTMX), BioSpecifics Technologies (BSTC) and Flexion Therapeutics (FLXN).
What other stocks do shareholders of CELYAD SA/ADR own?
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)
- Mr. Filippo Joseph Petti, CEO & Interim CFO
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 44)
- Nicolas Van Hoecke, Director of Investor Relations & Communications
- Mr. Philippe Dechamps, Chief Legal Officer (Age 49)
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Who are CELYAD SA/ADR's major shareholders?
CELYAD SA/ADR's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (6.99%) and Morgan Stanley (0.13%).
Which major investors are buying CELYAD SA/ADR stock?
CYAD stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and Morgan Stanley.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $12.30.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $121.40 million and generates $3.68 million in revenue each year. The company earns $-44,200,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. View Additional Information About CELYAD SA/ADR.
What is CELYAD SA/ADR's official website?
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
